Pfizer Exits Legacy Hypertension Brands in India With Novartis
Pfizer is exiting legacy hypertension brands in India by handing them to Novartis India. The deal is described as part of Pfizer reshaping its portfolio in that market, trimming mature cardiovascular products while positioning for higher value biologics. It’s also framed as managing patent risk and pricing pressure on older medicines, alongside oncology and obesity business development.